Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study (SFAF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01585961
Recruitment Status : Completed
First Posted : April 26, 2012
Results First Posted : January 26, 2015
Last Update Posted : January 26, 2015
Sponsor:
Information provided by (Responsible Party):
Biosense Webster, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a prospective, interventional, observational, unblinded, single-arm, multicenter registry of younger and older subjects with drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation.

Condition or disease Intervention/treatment
Atrial Fibrillation Paroxysmal Arrhythmia Device: Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)

Detailed Description:
This study is to measure the "real-world" acute procedural outcomes (procedural efficiency, acute safety, and effectiveness at one year) associated with use of the NAVISTAR® THERMOCOOL® SF Catheter in a clinical setting in subjects with drug refractory, recurrent symptomatic paroxysmal atrial fibrillation.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 511 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Study Start Date : April 2012
Actual Primary Completion Date : July 2014
Actual Study Completion Date : July 2014

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Catheter Ablation
These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and have provided written informed consent to participate in the study, including consent to undergo catheter ablation with the study device.
 Device: Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)
Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Total Fluoroscopy Time [ Time Frame: Day 0 (procedure) ]
    The fluoroscopy time will be measured for each phase (access, mapping, ablation, and validation) of the procedure and summed to derive the total time.

  2. Total Procedure Time [ Time Frame: Day 0 (procedure) ]
  3. Acute Procedural Success [ Time Frame: Day 0 (procedure) ]
    Confirmation of entrance and/or exit block across all targeted pulmonary veins.


Secondary Outcome Measures :
  1. Mean Number of Radiofrequency (RF) Applications [ Time Frame: Day 0 (procedure) ]
    RF applications is defined as the number of times RF energy is delivered during the procedure.

  2. Total Radiofrequency (RF) Time [ Time Frame: Day 0 (procedure) ]
    Total RF time is defined as the total time that RF energy is delivered during the procedure.

  3. Fluid Volume Delivered Via Ablation Catheter [ Time Frame: Day 0 (procedure) ]
  4. Number of Patients With Repeat Ablations [ Time Frame: 1 year ]
  5. Post-procedure AF Symptoms [ Time Frame: 12 Month Visit ]
    Symptoms attributed to paroxysmal atrial fibrillation reported at 12 month visit

  6. Number of Subjects With Lost Work Days, Related to AF, at 12 Month Visit [ Time Frame: 12 Month Visit ]
  7. Number of Patients With Inpatient Hospital Visit(s) Related to Atrial Fibrillation [ Time Frame: 12 Month Visit ]
  8. Number of Patients With Outpatient Emergency Visits Related to Atrial Fibrillation [ Time Frame: 12 Month Visit ]
  9. Change in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score [ Time Frame: Screening to 12 Month Visit ]
    Change is calculated as 12 month overall AFEQT score minus score at screening. An overall AFEQT score ranges from 0 to 100. A score of 0 corresponds to complete disability (or responding "extremely" limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability (or responding "not at all" limited, difficult or bothersome to all questions answered). Therefore a positive change in score corresponds to improvement in AF symptoms.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Older and younger patients with drug refractory, symptomatic paroxysmal atrial fibrillation.
Criteria

Inclusion Criteria:

  • Drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation
  • Age 18 years or older
  • Patients must be able and willing to provide written informed consent to participate in the study

Exclusion Criteria:

  • Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
  • Previous ablation for atrial fibrillation
  • Episodes of atrial fibrillation that last longer than 30 days and are terminated via cardioversion
  • Uncontrolled heart failure, or NYHA Class III or IV heart failure
  • Documented intra-atrial thrombus or other abnormality on pre-ablation echocardiogram
  • Contraindication to anticoagulation
  • Stroke, cardiac surgery, unstable angina, myocardial infarction or percutaneous coronary intervention within the past 3 months
  • Awaiting cardiac transplantation
  • Heart disease in which corrective surgery is anticipated within 6 months
  • Enrollment in investigational drug, biologic or device study
  • Subjects unwilling to comply with protocol or follow-up requirements
  • Patients who are pregnant
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01585961


Locations
Show Show 45 study locations
Sponsors and Collaborators
Biosense Webster, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Gery Tomassoni, MD Central Baptist Hospital
Principal Investigator: Scott Pollak, MD Florida Hospital - Orlando
Principal Investigator: Andy Tran, MD Scottsdale Healthcare Research Institute
Principal Investigator: Saumil Oza, MD St. Vincent's Ambulatory Care, Inc.
Principal Investigator: Steven Compton, MD Alaska Heart Institute, LLC
Principal Investigator: Anshul Patel, MD St. Joseph's Hospital of Atlanta
Principal Investigator: Robert Fishel, MD JFK Medical Center
Principal Investigator: Kenneth Civello, MD Cardiovascular Research Foundation of Louisiana
Principal Investigator: Gaurang Gandhi, MD Bethesda North Hospital
Principal Investigator: Alexandru Costea, MD University of Cincinnati
Principal Investigator: Sreedhar Billakanty, MD Riverside Methodist Hospital
Principal Investigator: H. James Wang, MD Florida Hospital Memorial Medical Center
Principal Investigator: John Harding, MD Central Bucks Specialists, Ltd.
Principal Investigator: Mohammed Khan, MD Alexian Brothers Medical Center
Principal Investigator: Vijay Jayachandran, MD Baylor All Saints Medical Center
Principal Investigator: Sree Karanam, MD Lutheran Medical Group, LLC
Principal Investigator: M. Craig Delaughter, MD Plaza Medical Center
Principal Investigator: Mohammad Jazayeri, MD Bellin Memorial Hospital, Inc.
Principal Investigator: Abdi Rasekh, MD Texas Heart Institute at St. Luke's Episcopal Hospital
Principal Investigator: Scott Allison, MD Heart Center Research, LLC
Principal Investigator: Alexander Mazur, MD University of Iowa Hospital & Clinics
Principal Investigator: Dhanunjaya Lakkireddy, MD University of Kansas Hospitals
Principal Investigator: Alan Wimmer, MD St. Luke's Hospital Mid American Heart Institute
Principal Investigator: Ali Hamzei, MD Scripps Clinical Research
Principal Investigator: Shalin Shah, MD Largo Medical Center
Principal Investigator: Michael Kutayli, MD Bryan LGH Heart Institute
Principal Investigator: John Mandrola, MD Baptist Hospital
Principal Investigator: Stuart Beldner, MD North Shore University Hospital
Principal Investigator: Joshua Moss, MD University of Chicago
Principal Investigator: Greg Bashian, MD Centennial Heart
Principal Investigator: Patrick Whalen, MD Vanderbilt Heart and Vascular Institute
Principal Investigator: Angelo Biviano, MD New York Presbyterian Hospital, Columbia University Medical Center
Principal Investigator: Hussam Abuissa, MD The Cardiac Center of Creighton University
Principal Investigator: Sumeet Mainigi, MD Albert Einstein Medical Center
Principal Investigator: Charles Athill, MD San Diego Cardiac Center
Principal Investigator: Edward Gerstenfeld, MD UCSF Medical Center
Principal Investigator: Michael Chisner, MD Cardiology Associates of Savannah
Principal Investigator: Vijendra Swarup, MD Arizona Heart Hospital
Principal Investigator: Ziad Issa, MD Prairie Education and Research Cooperative
Principal Investigator: Tariq Salam, MD Cardiac Study Center
Principal Investigator: Sung Lee, MD Washington Adventist Hospital
Principal Investigator: M. Magdy Migeed, MD Genesis Healthcare Systems
Principal Investigator: Jonathan Sussman, MD Morristown Medical Center
Principal Investigator: Bengt Herweg, MD Tampa General Hospital
Principal Investigator: Pierce Vatterott, MD United Heart and Vascular Clinic
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Biosense Webster, Inc.
ClinicalTrials.gov Identifier: NCT01585961    
Other Study ID Numbers: ThermoCool SF Phase IV
First Posted: April 26, 2012    Key Record Dates
Results First Posted: January 26, 2015
Last Update Posted: January 26, 2015
Last Verified: January 2015
Keywords provided by Biosense Webster, Inc.:
Symptomatic paroxysmal
Atrial fibrillation
Observational
Acute procedural outcomes
 Ablation
Drug refractory
Arrhythmia Recurrent
Symptomatic
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes